Nano Dimension Revenue Doubles as Company Pivots to Health AI
The additive manufacturing firm reported first-quarter revenue of $29.7 million, a 106% increase from the prior-year period.
Nano Dimension (NNDM), the additive manufacturing company, reported a significant increase in first-quarter revenue. The result arrived as the company began a fundamental shift in its business model, moving away from its core 3D printing operations toward AI-powered preventive health and diagnostics.
Revenue for the quarter rose 106% year-over-year to $29.7 million, compared to $14.4 million in the same period last year. Gross margin increased slightly to 40.8% from 40.6% year-over-year, while adjusted gross margin expanded to 45.9% from 43.3%.
Despite the revenue growth, losses widened. The company reported a net loss of $69.7 million, which included a $40.4 million impairment, compared to a loss of $25.5 million in the prior-year period. Adjusted EBITDA loss also grew to $12.5 million from a loss of $10.1 million.
To reduce costs, the company completed the sale of its AME and Fabrica product lines on April 6, 2026, for up to $12.5 million. The divestiture is expected to reduce annualized cash burn by approximately $10 million.
This restructuring coincides with a proposed business combination with Infinite Epigenetics, announced on June 15, 2026. Under the proposed terms, Infinite Epigenetics is valued at $890 million less a premium, while Nano Dimension's valuation is based on net cash plus a 20% premium and an estimated $20 million for Essemtec and other assets.
Nano Dimension suspended its full-year 2026 financial guidance on May 7, 2026, citing the acceleration of its strategic alternatives process and potential monetization actions.
Total cash, cash equivalents, deposits, and marketable securities stood at $441.6 million as of March 31, 2026, down from $459.6 million at the end of 2025.